Cancer vaccines harness the power of the immune system to stop tumors in their tracks. They work a little differently than ...

Trade body representing large pharmacies in England, Scotland and Wales is calling for patients to have greater access to life-saving vaccines ...

Worldwide, hepatitis B is thought to be the second deadliest infection; about 5% of the global population are infection and ...

In their effort to answer a decades-old biological question about how the hepatitis B virus (HBV) is able to establish ...

The hepatitis B vaccine is one of the very first vaccines your baby will get before she leaves the hospital. This vaccine protects her from a dangerous (but preventable!) liver infection and is given ...

The Advisory Committee on Immunization Practices (ACIP) that makes recommendations to the Centers for Disease Control and ...

Dynavax Technologies Corp (DVAX) reports record revenue for Heplisav-B, advances in vaccine programs, and strategic financial positioning despite rising R&D costs.

Researchers say if their results are confirmed through further study they are optimistic the approach could be used to treat ...

Dynavax reports record HEPLISAV-B revenue, 26% growth in 2024, and strong 2025 guidance. Insights on shingles vaccine progress & market expansion.

Dynavax Technologies Corporation ( NASDAQ: DVAX) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Paul Cox - Vice President, Investor Relations & Corporate Communications Ryan Spencer - ...